BeyondSpring Inc. (BYSI) stock forecast & analysis
0.7324
NasdaqCM · USD
Down: -0.3876, -34.6%
1 analysis
- Open
- 0.8100
- Previous close
- 1.12
- Day range
- 0.7108 – 0.8100
- 52-week range
- 0.5660 – 2.44
- Volume (shares)
- 1.28M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 41.12M
- P/E ratio
- Not available
- Dividend yield
- Not available
- Beta
- 0.06
- Market cap
- 30.12M
Market Scanner’s AI analysis of BeyondSpring Inc. (BYSI), updated September 2026: BeyondSpring's plinabulin Fast Track Designation and recent price surge dominated recent analyses.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of BeyondSpring Inc. (BYSI) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
BeyondSpring's plinabulin Fast Track Designation and recent price surge dominated recent analyses.
Recent analyses for BeyondSpring Inc. (BYSI) covered the FDA's granting of Fast Track Designation for plinabulin and a related strategic transaction to advance the DUBLIN-4 trial. The company also reported its Q2 2026 financial results. Concurrently, market analysis noted a strong bullish technical trend with significant short-term price increases, though indicators suggest the stock may be overextended.
BYSI news & sentiment
News reports highlighted positive developments including FDA Fast Track Designation for plinabulin and progress in clinical trials. Social media discussions focused on a strong upward price trend, though some noted potential overextension.
BYSI technical picture
BYSI's technical indicators showed a strong bullish trend and significant upward momentum, with price trading substantially above both the 50-day and 200-day SMAs. Momentum readings, including RSI and MFI, indicated strong buying pressure, though the price trading above the upper Bollinger Band suggested potential short-term overextension.
Fundamentals
The company reported $1.35M in revenue for the annual period ending December 31, 2022, with no subsequent revenue figures available. Consistent net and operating losses were reported for both the annual period ending December 31, 2022, and the most recent reported quarter ending June 30, 2026.
Factors discussed — upside
- FDA Fast Track Designation for plinabulin in post-ICI non-squamous NSCLC
- Strategic transaction to advance the global Phase 3 DUBLIN-4 trial
- Strong bullish technical trend with significant upward momentum
- Recent rapid price increase (+51.4% 7-day, +68.4% 30-day)
- Extremely high Money Flow Index (MFI) at 99.02
Factors discussed — risks
- Longer-term downtrend prior to recent rally (-37.4% 91-day)
- Relative Strength Index (RSI) above overbought threshold (75.83)
- Price trading above the upper Bollinger Band, suggesting potential overextension
- Consistent net losses and operating losses reported
- Limited recent revenue data available
- Clinical trial advancement
- Regulatory designation
- Technical indicators
- Financial performance
Summary updated .
BYSI technical indicators
Common technical indicators for BYSI, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 0.83 | Price below |
| 10-day exponential moving average | 0.79 | Price below |
| Relative strength index (14-day) | 47.52 | Neutral |
| MACD line (12/26/9) | 0.0043 | Above its signal line |
| Bollinger bands (20-day, 2σ) | 0.51 – 0.94 | Price inside the bands |
Analyses
Recent BYSI.US analyses are locked — sign in to read them or generate a fresh one.
Frequently asked questions
- What is the bull case for BeyondSpring Inc.?
- The bull case centers on the FDA's Fast Track Designation for plinabulin and a strategic transaction to advance the DUBLIN-4 trial, alongside strong recent price increases and bullish technical indicators suggesting significant upward momentum.
- What are the risks for BeyondSpring Inc.?
- Risks include consistent net and operating losses, limited recent revenue data, and a longer-term downtrend prior to the recent rally. Additionally, technical indicators suggest the stock may be overextended in the short term.
- Is BeyondSpring Inc. bullish or bearish?
- Recent AI analyses of BeyondSpring Inc. examined factors on both sides. Discussed upside: The bull case centers on the FDA's Fast Track Designation for plinabulin and a strategic transaction to advance the DUBLIN-4 trial, alongside strong recent price increases and bullish technical indicators suggesting significant upward momentum. Discussed risks: Risks include consistent net and operating losses, limited recent revenue data, and a longer-term downtrend prior to the recent rally. Additionally, technical indicators suggest the stock may be overextended in the short term. These are descriptive observations, not a recommendation.
- What is the latest sentiment on BeyondSpring Inc.?
- News reports highlighted positive developments including FDA Fast Track Designation for plinabulin and progress in clinical trials. Social media discussions focused on a strong upward price trend, though some noted potential overextension.
- How does Market Scanner analyse BeyondSpring Inc.?
- Every analysis of BeyondSpring Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
- Bundles used
- gemini-low-v2
Run a fresh BYSI.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.